Drug Trial Radar · NCT04679103
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
Last checked: Nov 20, 2026Latest source record: Dec 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
May 3, 2018
Primary completion
Apr 20, 2020
Study completion Apr 20, 2020
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Dec 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A safety and immunogenicity study in long-term treatment of Eculizumab (JSC "GENERIUM", Russian Federation) in patients with paroxysmal nocturnal hemoglobinuria, who have been involved earlier in the clinical trials of Eculizumab (JSC "GENERIUM", Russian Federation).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
Eculizumab (JSC GENERIUM, Russia)Biological
Eculizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency and severity of adverse events (AEs), serious adverse events (SAEs), including those associated with the use of the study drug.Time frame: 6 months
- The number and proportion of patients with antidrug antibodies; titer of antidrug antibodies and their neutralizing activity.Time frame: 6 months
- Changes in vital signs during the study.Time frame: 6 months
- Changes in physical examination during the study.Time frame: 6 months
- Changes in ECG during the study.Time frame: 6 months
- Changes in Doppler echocardiography during the study.Time frame: 6 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital"
Chelyabinsk, Chelyabinsk Oblast, Russia
Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency"
Kirov, Kirov Oblast, Russia
Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov"
Saint Petersburg, Leningradskaya Oblast', Russia
Federal State Budgetary Institution "National Medical Research Center of Hematology" of the Ministry of Health of the Russian Federation
Moscow, Moscow Oblast, Russia
State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin of the Moscow Department of Health
Moscow, Moscow Oblast, Russia
State budgetary institution of health care of the Moscow region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky"
Moscow, Moscow Oblast, Russia
State budgetary institution of the Rostov region "Rostov Regional Clinical Hospital"
Rostov-on-Don, Rostov Oblast, Russia
Federal State Budgetary Educational Institution of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
Samara, Samara Oblast, Russia
State Budgetary Healthcare Institution of the Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital No. 1"
Yekaterinburg, Sverdlovsk Oblast, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.